Alto Neuroscience, Inc. (ANRO)
Healthcare
Biotechnology
27.10 $
-5.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Alto Neuroscience, Inc. (ANRO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 67.4% of the shares are freely tradable; institutional investors hold 82.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
82.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
4.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
67.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
5.5%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
35Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Alpha Wave Global LP | 10.57 | 3,707,757 | +0.0 | 03/31/2026 |
| COMMODORE CAPITAL LP | 7.76 | 2,723,196 | +49.4 | 03/31/2026 |
| Vestal Point Capital LP | 5.88 | 2,064,075 | -16.9 | 03/31/2026 |
| Perceptive Advisors LLC | 5.73 | 2,009,893 | +12.6 | 03/31/2026 |
| Vanguard Group Inc | 3.89 | 1,365,847 | +23.6 | 12/31/2025 |
| Spruce Street Capital LP | 3.78 | 1,325,210 | +494.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.44 | 1,207,025 | +0.0 | 03/31/2026 |
| Franklin Resources Inc | 3.14 | 1,101,874 | -1.6 | 03/31/2026 |
| Vivo Capital, LLC | 2.95 | 1,035,551 | +0.0 | 03/31/2026 |
| Armistice Capital, LLC | 2.60 | 912,000 | -40.6 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.